Results 51 to 60 of about 2,101 (161)

Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their ...
Mohamed Hassanein, Li Xi, Rathi D. Ryan, Zhan (Harold) Ye, Nessy Tania, Yamato Sano, Joshua Varghese, Diogo Branquinho, Anna Sapone   +8 more
wiley   +1 more source

Selective Drug‐Free Active Surveillance in Ulcerative Colitis: Biomarker‐Guided, Patient‐Centered Approach

JGH Open, Volume 10, Issue 4, April 2026.
ABSTRACT Ulcerative colitis (UC) is traditionally managed with long‐term 5‐aminosalicylic acid (5‐ASA) administration. However, in real‐world practice, carefully selected low‐risk patients in sustained deep remission may remain stable without continuous therapy.
Tsutomu Nishida, Naoto Osugi, Takahiro Amano, Takeo Yoshihara   +3 more
wiley   +1 more source

Prescription Behaviour and Drug Interactions of Acid Suppressants With Tyrosine Kinase Inhibitors in Patients With Leukaemia: Data From Germany

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Tyrosine kinase inhibitors (TKIs) are essential in treating chronic myeloid leukaemia (CML) and other malignancies. Their absorption, however, is highly pH‐dependent, making them susceptible to interactions with acid‐suppressing agents such as proton pump inhibitors (PPIs), histamine‐2 receptor antagonists (H2RAs) and antacids ...
Marek Lapka, Anna Khryakova, Anastasiia Nazmutdinova, Chrysostomos Charalambous, Jan Bosak, Jiri Sliva   +5 more
wiley   +1 more source

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

RMD Open
Objectives Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major adverse ...
Zoltan Szekanecz, Yoshiya Tanaka, Laurent Peyrin-Biroulet, Stefan Schreiber, René Westhovens, Xavier Mariette, Chris Watson, C Janneke van der Woude, Hugo ten Cate, Andreas Stallmach, Christina Charles-Schoeman, Sandrine Aspeslagh, Marc Schmalzing, Margaux Faes, Sven Borchmann, Christine Rudolph, Edmund V Ekoka Omoruyi, Paul Van Hoek, Ernest HS Choy, Tomasz Masior   +19 more
doaj   +1 more source

Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses

Rheumatology and Therapy, 2023
Filgotinib is an oral preferential Janus kinase 1 inhibitor that demonstrated significant reductions in radiographic progression, with an acceptable tolerability and safety profile, vs placebo in patients with rheumatoid arthritis (RA) and an inadequate ...
Yoshiya Tanaka, Tsutomu Takeuchi, Tatsuya Atsumi, Bernard G. Combe, Daniel Aletaha, Toshihiko Kaise, Vijay Rajendran   +6 more
doaj   +1 more source

Cholesterol Promotes Lung Adenocarcinoma Brain Metastasis by Stabilizing EGFR Protein to Drive EMT, Metabolic Reprogramming, and Premetastatic Niche Formation

Advanced Science, Volume 13, Issue 17, 23 March 2026.
Cholesterol is revealed as a multitasking fuel for lung adenocarcinoma brain metastasis: it locks EGFR at the membrane to sustain AKT/NF‐κB–driven glycolysis and EMT, loosens the blood–brain barrier by promoting Claudin‐5 loss, and rewires microglia through IL‐4R lipid‐raft–JAK1/STAT6 signaling.
Ying Chen, Xiaoteng Cui, Xinyi Shi, Xu Yang, Yujing Cao, Haolin LI, Qi Zhan, Qixue Wang, Ang Li, Qihong Cheng, Yunfei Wang, Junhu Zhou, MingJie Wang, Chunsheng Kang, Xiaomin Liu   +14 more
wiley   +1 more source

Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial

Trials, 2023
Background Administration of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs has dramatically improved even the clinical outcomes in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate ...
Toshimasa Shimizu, Shin-ya Kawashiri, Shimpei Morimoto, Yurika Kawazoe, Shohei Kuroda, Rina Kawasaki, Yasuko Ito, Rieko Kiya, Shuntaro Sato, Hiroshi Yamamoto, Atsushi Kawakami   +10 more
doaj   +1 more source

From Pharmaceutical to Biophysical Therapies: New Horizons in Inflammatory Bowel Disease Management

JCC Plus, Volume 1, Issue 2, March 2026.
Important limitations exist in the current pharmacological landscape of Inflammatory Bowel Disease (IBD), such as variable response rates and treatment‐limiting adverse effects. In this review, we perform a critical assessment of the current literature on novel multimodal biophysical approaches showing alternative mechanisms of action to, and potential
Benedetta Ricchi, Alejandra A. Carriles, Samuel Elias Pineda Chavez, Stefanos Bonovas, Arianna Dal Buono, Cristina Bezzio, Alessandro Armuzzi, Stefania Vetrano   +7 more
wiley   +1 more source

Targeted therapy of inflammatory bowel diseases: realities and prospects

Медицинский совет, 2018
This review article was designed to systematize the literature data concerning the role of targeted therapy in the treatment of patients with inflammatory bowel diseases.
I. V. Maev, D. N. Andreev
doaj   +1 more source

Efficacy of Filgotinib for Treating Chronic Antibiotic‐Dependent Pouchitis: A Pilot Study

JCC Plus, Volume 1, Issue 2, March 2026.
Chronic pouchitis after restorative proctocolectomy for ulcerative colitis is often difficult to treat. This study evaluated the efficacy of filgotinib for patients with chronic pouchitis. Some patients with chronic pouchitis may be controlled with filgotinib.
Motoi Uchino, Yuki Horio, Ryuichi Kuwahara, Kurando Kusunoki, Kentaro Nagano, Kazunori Nomura, Yusuke Tomoo, Kozo Kataoka, Kei Kimura, Jihyung Song, Ayako Imada, Kazuma Ito, Yuko Fukumoto, Mizuki Koba, Masataka Ikeda, Hiroki Ikeuchi   +15 more
wiley   +1 more source